valproic acid has been researched along with Cancer of Cervix in 17 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twelve newly diagnosed patients with cervical cancer were treated with magnesium valproate after a baseline tumor biopsy and blood sampling at the following dose levels (four patients each): 20 mg/kg; 30 mg/kg, or 40 mg/kg for 5 days via oral route." | 2.71 | Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study. ( Angeles, E; Cabrera, G; Candelaria, M; Cantu, D; Cetina, L; Chavez-Blanco, A; Duenas-Gonzalez, A; Garcia-Lopez, P; Gonzalez-Fierro, A; Perez-Cardenas, E; Perez-Plasencia, C; Segura-Pacheco, B; Taja-Chayeb, L; Trejo-Becerril, C; Zambrano, P, 2005) |
| "Cervical cancer is one of the most prevalent malignancies in women worldwide." | 1.43 | Valproic acid inhibits the angiogenic potential of cervical cancer cells via HIF-1α/VEGF signals. ( Chi, Y; Du, R; Tang, W; You, W; Zhao, Y; Zheng, J, 2016) |
| "Treatment with valproic acid, an HDAC inhibitor, could significantly increase the expression of Oct4 in C-33A cells, but only slightly increased Oct4 in CaSki cells." | 1.38 | HDAC1/DNMT3A-containing complex is associated with suppression of Oct4 in cervical cancer cells. ( Gong, W; He, F; Huang, G; Liu, D; Zhang, L; Zheng, Y; Zhou, P, 2012) |
| " Chronic administration of VPA had a net cytostatic effect that resulted in a statistically significant reduction of tumour growth and improved survival advantages in tumour xenografts studies." | 1.35 | Valproic acid inhibits the growth of cervical cancer both in vitro and in vivo. ( Höti, N; Huang, X; Sami, S; Shen, Z; Xu, HM, 2008) |
| "In some cervical cancer cell lines, these drugs led to increased transcription of p53, and increased its stabilization due to acetylation at lysines 273 and 282, which allowed a higher bax-protein transactivating effect." | 1.34 | The effects of DNA methylation and histone deacetylase inhibitors on human papillomavirus early gene expression in cervical cancer, an in vitro and clinical study. ( Cantú, D; Contreras-Paredes, A; de la Cruz-Hernández, E; Dueñas-González, A; Lizano, M; Mohar, A; Pérez-Cárdenas, E, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (17.65) | 29.6817 |
| 2010's | 12 (70.59) | 24.3611 |
| 2020's | 2 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Rocha, MA | 1 |
| de Campos Vidal, B | 1 |
| Mello, MLS | 1 |
| Hidayatullah, A | 1 |
| Putra, WE | 1 |
| Sustiprijatno, S | 1 |
| Rifa'i, M | 1 |
| Widiastuti, D | 1 |
| Heikal, MF | 1 |
| Permatasari, GW | 1 |
| Han, BR | 1 |
| You, BR | 1 |
| Park, WH | 1 |
| Li, J | 1 |
| Bonifati, S | 1 |
| Hristov, G | 1 |
| Marttila, T | 1 |
| Valmary-Degano, S | 1 |
| Stanzel, S | 1 |
| Schnölzer, M | 1 |
| Mougin, C | 1 |
| Aprahamian, M | 1 |
| Grekova, SP | 1 |
| Raykov, Z | 1 |
| Rommelaere, J | 1 |
| Marchini, A | 1 |
| Feng, D | 2 |
| Wu, J | 1 |
| Tian, Y | 1 |
| Zhou, H | 2 |
| Zhou, Y | 2 |
| Hu, W | 1 |
| Zhao, W | 2 |
| Wei, H | 2 |
| Ling, B | 2 |
| Ma, C | 1 |
| Mani, E | 1 |
| Medina, LA | 1 |
| Isaac-Olivé, K | 1 |
| Dueñas-González, A | 6 |
| Zhao, Y | 1 |
| You, W | 1 |
| Zheng, J | 1 |
| Chi, Y | 1 |
| Tang, W | 1 |
| Du, R | 1 |
| Aebischer, B | 1 |
| Elsig, S | 1 |
| Taeymans, J | 1 |
| Pomp, S | 1 |
| Kuhness, D | 1 |
| Barcaro, G | 1 |
| Sementa, L | 1 |
| Mankad, V | 1 |
| Fortunelli, A | 1 |
| Sterrer, M | 1 |
| Netzer, FP | 1 |
| Surnev, S | 1 |
| Schmieder, AH | 1 |
| Caruthers, SD | 1 |
| Keupp, J | 1 |
| Wickline, SA | 1 |
| Lanza, GM | 1 |
| Lowe, J | 1 |
| Wodarcyk, AJ | 1 |
| Floyd, KT | 1 |
| Rastogi, N | 1 |
| Schultz, EJ | 1 |
| Swager, SA | 1 |
| Chadwick, JA | 1 |
| Tran, T | 1 |
| Raman, SV | 1 |
| Janssen, PM | 1 |
| Rafael-Fortney, JA | 1 |
| Alcalay, RN | 1 |
| Levy, OA | 1 |
| Wolf, P | 1 |
| Oliva, P | 1 |
| Zhang, XK | 1 |
| Waters, CH | 1 |
| Fahn, S | 1 |
| Kang, U | 1 |
| Liong, C | 1 |
| Ford, B | 1 |
| Mazzoni, P | 1 |
| Kuo, S | 1 |
| Johnson, A | 1 |
| Xiong, L | 1 |
| Rouleau, GA | 1 |
| Chung, W | 1 |
| Marder, KS | 1 |
| Gan-Or, Z | 1 |
| Kamei, K | 1 |
| Terao, T | 1 |
| Katayama, Y | 1 |
| Hatano, K | 1 |
| Kodama, K | 1 |
| Shirahama, M | 1 |
| Sakai, A | 1 |
| Hirakawa, H | 1 |
| Mizokami, Y | 1 |
| Shiotsuki, I | 1 |
| Ishii, N | 1 |
| Inoue, Y | 1 |
| Akboga, MK | 1 |
| Yayla, C | 1 |
| Balci, KG | 1 |
| Ozeke, O | 1 |
| Maden, O | 1 |
| Kisacik, H | 1 |
| Temizhan, A | 1 |
| Aydogdu, S | 1 |
| Zhu, J | 2 |
| Ying, SH | 1 |
| Feng, MG | 1 |
| Zhang, XG | 1 |
| Li, H | 1 |
| Wang, L | 1 |
| Hao, YY | 1 |
| Liang, GD | 1 |
| Ma, YH | 1 |
| Yang, GS | 1 |
| Hu, JH | 1 |
| Pfeifer, L | 1 |
| Goertz, RS | 1 |
| Neurath, MF | 1 |
| Strobel, D | 1 |
| Wildner, D | 1 |
| Lin, JT | 1 |
| Yang, XN | 1 |
| Zhong, WZ | 1 |
| Liao, RQ | 1 |
| Dong, S | 1 |
| Nie, Q | 1 |
| Weng, SX | 1 |
| Fang, XJ | 1 |
| Zheng, JY | 1 |
| Wu, YL | 1 |
| Řezanka, T | 1 |
| Kaineder, K | 1 |
| Mezricky, D | 1 |
| Řezanka, M | 1 |
| Bišová, K | 1 |
| Zachleder, V | 1 |
| Vítová, M | 1 |
| Rinker, JA | 1 |
| Marshall, SA | 1 |
| Mazzone, CM | 1 |
| Lowery-Gionta, EG | 1 |
| Gulati, V | 1 |
| Pleil, KE | 1 |
| Kash, TL | 1 |
| Navarro, M | 1 |
| Thiele, TE | 1 |
| Zhang, Y | 1 |
| Huang, Y | 1 |
| Jin, Z | 1 |
| Li, X | 1 |
| Li, B | 1 |
| Xu, P | 1 |
| Huang, P | 1 |
| Liu, C | 1 |
| Fokdal, L | 1 |
| Sturdza, A | 1 |
| Mazeron, R | 1 |
| Haie-Meder, C | 1 |
| Tan, LT | 1 |
| Gillham, C | 1 |
| Šegedin, B | 1 |
| Jürgenliemk-Schultz, I | 1 |
| Kirisits, C | 1 |
| Hoskin, P | 1 |
| Pötter, R | 1 |
| Lindegaard, JC | 1 |
| Tanderup, K | 1 |
| Levin, DE | 1 |
| Schmitz, AJ | 1 |
| Hines, SM | 1 |
| Hines, KJ | 1 |
| Tucker, MJ | 1 |
| Brewer, SH | 1 |
| Fenlon, EE | 1 |
| Álvarez-Pérez, S | 1 |
| Blanco, JL | 1 |
| Peláez, T | 1 |
| Martínez-Nevado, E | 1 |
| García, ME | 1 |
| Puckerin, AA | 1 |
| Chang, DD | 1 |
| Subramanyam, P | 1 |
| Colecraft, HM | 1 |
| Dogan, H | 1 |
| Coteli, E | 1 |
| Karatas, F | 1 |
| Ceylan, O | 1 |
| Sahin, MD | 1 |
| Akdamar, G | 1 |
| Kryczyk, A | 1 |
| Żmudzki, P | 1 |
| Hubicka, U | 1 |
| Giovannelli, D | 1 |
| Chung, M | 1 |
| Staley, J | 1 |
| Starovoytov, V | 1 |
| Le Bris, N | 1 |
| Vetriani, C | 1 |
| Chen, W | 1 |
| Wu, L | 1 |
| Liu, X | 1 |
| Shen, Y | 1 |
| Liang, Y | 1 |
| Tan, H | 1 |
| Yang, Y | 2 |
| Liu, Q | 1 |
| Wang, M | 1 |
| Liu, L | 1 |
| Wang, X | 1 |
| Liu, B | 1 |
| Liu, GH | 1 |
| Zhu, YJ | 1 |
| Wang, JP | 1 |
| Che, JM | 1 |
| Chen, QQ | 1 |
| Chen, Z | 1 |
| Maucksch, U | 1 |
| Runge, R | 1 |
| Wunderlich, G | 1 |
| Freudenberg, R | 1 |
| Naumann, A | 1 |
| Kotzerke, J | 1 |
| Feng, S | 1 |
| Lv, J | 1 |
| Sun, L | 1 |
| Liu, M | 1 |
| Sami, S | 1 |
| Höti, N | 1 |
| Xu, HM | 1 |
| Shen, Z | 1 |
| Huang, X | 1 |
| Candelaria, M | 3 |
| Cetina, L | 3 |
| Pérez-Cárdenas, E | 5 |
| de la Cruz-Hernández, E | 4 |
| González-Fierro, A | 4 |
| Trejo-Becerril, C | 4 |
| Taja-Chayeb, L | 4 |
| Chanona, J | 1 |
| Arias, D | 1 |
| Coronel, J | 1 |
| Pacheco, I | 1 |
| Arias-Bofill, D | 1 |
| Vidal, S | 2 |
| Perez-Plasencia, C | 2 |
| Chávez-Blanco, A | 2 |
| Gutiérrez, O | 1 |
| Dominguez, GI | 1 |
| Trujillo, JE | 1 |
| Cao, Z | 1 |
| Li, C | 1 |
| Zhang, L | 2 |
| Ma, J | 1 |
| Liu, R | 1 |
| Liu, D | 1 |
| Zhou, P | 1 |
| Gong, W | 1 |
| Huang, G | 1 |
| Zheng, Y | 1 |
| He, F | 1 |
| Segura-Pacheco, B | 1 |
| Cantu, D | 2 |
| Garcia-Lopez, P | 1 |
| Zambrano, P | 1 |
| Cabrera, G | 1 |
| Angeles, E | 1 |
| Contreras-Paredes, A | 1 |
| Mohar, A | 1 |
| Lizano, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| "Phase III Clinical Trial: Evaluation of the Combination of TRANSKRIP ® Plus Carboplatin and Paclitaxel as First Line Chemotherapy on Survival of Patients With Recurrent - Persistent Cervical Cancer"[NCT02446652] | Phase 3 | 230 participants (Anticipated) | Interventional | 2015-07-31 | Not yet recruiting | ||
| Phase 0 Clinical Trial With Valproic Acid as a Chemopreventive Agent in Patients With Head and Neck Squamous Cell Carcinoma Previously Treated[NCT02608736] | Early Phase 1 | 42 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for valproic acid and Cancer of Cervix
| Article | Year |
|---|---|
Topics: AC133 Antigen; Acenaphthenes; Acer; Acrosome Reaction; Adult; Agaricales; Aged; Aged, 80 and over; A | 2016 |
2 trials available for valproic acid and Cancer of Cervix
| Article | Year |
|---|---|
A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Double-Blind | 2011 |
Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study.
Topics: Acetylation; Adult; Aged; Dose-Response Relationship, Drug; Female; Histone Deacetylases; Histones; | 2005 |
Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study.
Topics: Acetylation; Adult; Aged; Dose-Response Relationship, Drug; Female; Histone Deacetylases; Histones; | 2005 |
Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study.
Topics: Acetylation; Adult; Aged; Dose-Response Relationship, Drug; Female; Histone Deacetylases; Histones; | 2005 |
Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study.
Topics: Acetylation; Adult; Aged; Dose-Response Relationship, Drug; Female; Histone Deacetylases; Histones; | 2005 |
14 other studies available for valproic acid and Cancer of Cervix
| Article | Year |
|---|---|
Sodium Valproate Modulates the Methylation Status of Lysine Residues 4, 9 and 27 in Histone H3 of HeLa Cells.
Topics: DNA Methylation; Female; HeLa Cells; Histones; Humans; Jumonji Domain-Containing Histone Demethylase | 2023 |
Concatenation of molecular docking and dynamics simulation of human papillomavirus type 16 E7 oncoprotein targeted ligands: In quest of cervical cancer's treatment.
Topics: Female; Human Papillomavirus Viruses; Humans; Ligands; Molecular Docking Simulation; Oncogene Protei | 2023 |
Valproic acid inhibits the growth of HeLa cervical cancer cells via caspase-dependent apoptosis.
Topics: Apoptosis; Caspase Inhibitors; Caspases; Cell Proliferation; Female; Glutathione; HeLa Cells; Humans | 2013 |
Synergistic combination of valproic acid and oncolytic parvovirus H-1PV as a potential therapy against cervical and pancreatic carcinomas.
Topics: Animals; Apoptosis; Carcinoma; Cell Line, Tumor; Disease Models, Animal; Female; HeLa Cells; Histone | 2013 |
Targeting of histone deacetylases to reactivate tumour suppressor genes and its therapeutic potential in a human cervical cancer xenograft model.
Topics: Animals; Antineoplastic Agents; beta Catenin; Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; | 2013 |
Radiosensitization of cervical cancer cells with epigenetic drugs hydralazine and valproate.
Topics: Cell Line, Tumor; Cell Survival; Combined Modality Therapy; DNA Methylation; DNA Modification Methyl | 2014 |
Valproic acid inhibits the angiogenic potential of cervical cancer cells via HIF-1α/VEGF signals.
Topics: Angiogenesis Inhibitors; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Enzyme-Linked Immu | 2016 |
Valproic acid exhibits different cell growth arrest effect in three HPV-positive/negative cervical cancer cells and possibly via inducing Notch1 cleavage and E6 downregulation.
Topics: Cell Cycle Checkpoints; Cell Proliferation; Diamines; Female; Gene Expression Regulation, Neoplastic | 2016 |
Valproic acid inhibits the growth of cervical cancer both in vitro and in vivo.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Enzyme Inhibitors; | 2008 |
Epigenetic therapy and cisplatin chemoradiation in FIGO stage IIIB cervical cancer.
Topics: Adult; Aged; Antineoplastic Agents; Brachytherapy; Cisplatin; Combined Modality Therapy; Epigenesis, | 2010 |
Transcriptional changes induced by epigenetic therapy with hydralazine and magnesium valproate in cervical carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Clinical Trials as Topic; DNA Methylation | 2011 |
Combination of valproic acid and ATRA restores RARβ2 expression and induces differentiation in cervical cancer through the PI3K/Akt pathway.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Differentiation; Cell Line, Tumor; | 2012 |
HDAC1/DNMT3A-containing complex is associated with suppression of Oct4 in cervical cancer cells.
Topics: DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; Female; Histone Deacetylase 1; Human | 2012 |
The effects of DNA methylation and histone deacetylase inhibitors on human papillomavirus early gene expression in cervical cancer, an in vitro and clinical study.
Topics: Acetylation; Alphapapillomavirus; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; DNA M | 2007 |